Company intelligence / Profile preview
Enkefalos Biosciences
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
TH104 underwent IND approval and is advancing to Phase 2 for chronic pruritus in PBC; early clinical data suggests effective itch suppression. Pipeline includes oral biologics and multi-specific/ADC antibody programs in preclinical development targeting oncology and immunology indications
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- Small moleculeOral biologicBispecific monoclonal antibodyAntibody-drug conjugate
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
OmniAb (antibody discovery technology license)
Beyond the preview
Go deeper on Enkefalos Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enkefalos Biosciences.